Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

Oppenheimer initiated coverage on Gossamer Bio Inc (NASDAQ:GOSS), a clinical-stage biopharmaceutical company, with an Outperform rating and a price target of $9. Gossamer Bio is focused on developing

BenzingaJun 26 02:39

Gossamer Bio And 2 Other Stocks Under $2 Insiders Are Buying

The Dow Jones index closed higher by over 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders in

BenzingaJun 25 20:51

Express News | Gossamer Bio Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $9

BreakingsJun 25 20:20

Gossamer Bio Initiated at Outperform by Oppenheimer

Gossamer Bio Initiated at Outperform by Oppenheimer

Dow JonesJun 25 17:51

Oppenheimer Initiates Coverage On Gossamer Bio With Outperform Rating, Announces Price Target of $9

Oppenheimer analyst Andreas Argyrides initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Outperform rating and announces Price Target of $9.

BenzingaJun 25 17:40

Gossamer Bio(GOSS.US) Officer Buys US$250.28K in Common Stock

$Gossamer Bio(GOSS.US)$ Officer Hasnain Faheem purchased 372K shares of common stock on Jun 21, 2024 at an average price of $0.6728 for a total value of $250.28K.Source: Announcement What is statement

Futu NewsJun 25 06:34